Halozyme Therapeutics (HALO)
NASDAQ:HALO
Want to see HALO full AI Analyst Report?
HALO Stock Chart & Stats
$69.29
$1.48(2.88%)
At close: 4:00 PM EST
$69.29
$1.48(2.88%)
Day’s Range― - ―
52-Week Range$51.06 - $82.22
Previous CloseN/A
Volume1.23M
Average Volume (3M)1.61M
Market Cap
$8.18B
Enterprise Value$8.08B
Total Cash (Recent Filing)$318.62M
Total Debt (Recent Filing)$2.14B
Price to Earnings (P/E)12.7
Beta0.42
Next Earnings
Aug 11, 2026EPS Estimate
1.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.92
Shares Outstanding118,613,000
10 Day Avg. Volume2,208,311
30 Day Avg. Volume1,614,573
Financial Highlights & Ratios
PEG Ratio-1.04
Price to Book (P/B)165.22
Price to Sales (P/S)5.77
P/FCF Ratio12.51
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue5.36
Enterprise Value/Gross Profit6.96
Enterprise Value/Ebitda8.41
Forecast
1Y Price Target
$84.48Price Target Upside21.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)8.1
Revenue Forecast (FY)$1.77B
Bulls Say, Bears Say
Bulls Say
Commercial Execution And GuidanceRaised revenue guidance and royalty outperformance reflect strong commercial momentum from multiple ENHANZE-enabled launches, supporting the view that near-term growth targets are achievable.
Platform Partnership ValidationAnalyst views the Vertex collaboration as strategic validation that Hypercon is partnerable, increasing confidence in technical adoption and potential commercial translation for high-concentration, small-volume biologics.
Royalty Mix ClarityDisclosure indicates Vyvgart Hytrulo contributes a larger share of Halozyme's royalties and benefits from stronger patent protection, reducing reliance on any single royalty stream and improving revenue visibility.
Bears Say
Collaboration Execution UncertaintyUncertainty remains about how the Vertex collaboration and other partner deals will impact prior royalty projections, creating downside risk if financial terms or execution differ from expectations.
Cost And Margin PressureConfirmed increases in research and development spending tied to recent acquisitions will raise operating expenses and could pressure near-term profitability and margins.
Patent Expiration RiskPatent expirations for ENHANZE and key royalties such as Darzalex could erode long-term revenue if new launches, patent strategies, or acquisitions do not adequately replace lost sales.
Halozyme News
HALO FAQ
What was Halozyme Therapeutics’s price range in the past 12 months?
Halozyme Therapeutics lowest stock price was $51.06 and its highest was $82.22 in the past 12 months.
What is Halozyme Therapeutics’s market cap?
Halozyme Therapeutics’s market cap is $8.18B.
When is Halozyme Therapeutics’s upcoming earnings report date?
Halozyme Therapeutics’s upcoming earnings report date is Aug 11, 2026 which is in 82 days.
How were Halozyme Therapeutics’s earnings last quarter?
Halozyme Therapeutics released its earnings results on May 11, 2026. The company reported $1.6 earnings per share for the quarter, beating the consensus estimate of $1.545 by $0.055.
Is Halozyme Therapeutics overvalued?
According to Wall Street analysts Halozyme Therapeutics’s price is currently Undervalued.
Does Halozyme Therapeutics pay dividends?
Halozyme Therapeutics does not currently pay dividends.
What is Halozyme Therapeutics’s EPS estimate?
Halozyme Therapeutics’s EPS estimate is 1.81.
How many shares outstanding does Halozyme Therapeutics have?
Halozyme Therapeutics has 118,613,000 shares outstanding.
What happened to Halozyme Therapeutics’s price movement after its last earnings report?
Halozyme Therapeutics reported an EPS of $1.6 in its last earnings report, beating expectations of $1.545. Following the earnings report the stock price went up 6.806%.
Which hedge fund is a major shareholder of Halozyme Therapeutics?
Currently, no hedge funds are holding shares in HALO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Halozyme Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$84.48 (21.93% Upside)
$84.48 (21.93% Upside)
Blogger Sentiment
Bullish
HALO Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 138.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▲ 25.5%
Last 30 Days ▲ 25.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
29.05%
12-Months-Change
Fundamentals
Return on Equity
126.27%
Trailing 12-Months
Asset Growth
21.68%
Trailing 12-Months
Company Description
Halozyme Therapeutics
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
HALO Company Deck
HALO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong, broad-based commercial and financial momentum: double-digit growth across top-line, royalties, adjusted EBITDA and EPS with reaffirmed 2026 guidance, new $1B buyback, and multiple near- and long-term revenue drivers (ENHANZE expansion, Hypercon, Surf Bio and new CLAs). Key near-term challenges include higher leverage and increased operating expenses from recent acquisitions, and manufacturing/timing execution risk for Hypercon and continued reliance on co-formulation IP to extend royalty duration. On balance, the positive metrics, clear capital allocation plans and pipeline/deal momentum outweigh these operational and timing risks.View all HALO earnings summariesHALO Revenue Breakdown
54.01% Royalties
36.28% Product sales
9.71% Revenues under collaborative agreements
HALO Stock 12 Month Forecast
Average Price Target
$84.48
▲(21.93% Upside)
Technical Analysis
Corcept Therapeutics
―
Ionis Pharmaceuticals
―
Bio-Techne
―
Moderna
―
Roivant Sciences
―
Ownership Overview
1.20% Insiders
27.38% Mutual Funds
27.59% Other Institutional Investors
15.48% Public Companies and Individual Investors